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Abstract
Background: Significant pain from HIV-associated sensory neuropathy (HIV-SN) affects ,40% of HIV infected individuals
treated with antiretroviral therapy (ART). The prevalence of HIV-SN has increased despite the more widespread use of ART.
With the global HIV prevalence estimated at 33 million, and with infected individuals gaining increased access to ART,
painful HIV-SN represents a large and expanding world health problem. There is an urgent need to develop effective pain
management strategies for this condition.
Method and Findings: Objective: To evaluate the clinical effectiveness of analgesics in treating painful HIV-SN. Design:
Systematic review and meta-analysis. Data sources: Medline, Cochrane central register of controlled trials, www.clinicaltrials.
gov, www.controlled-trials.com and the reference lists of retrieved articles. Selection criteria: Prospective, double-blinded,
randomised controlled trials (RCTs) investigating the pharmacological treatment of painful HIV-SN with sufficient quality
assessed using a modified Jadad scoring method. Review methods: Four authors assessed the eligibility of articles for
inclusion. Agreement of inclusion was reached by consensus and arbitration. Two authors conducted data extraction and
analysis. Dichotomous outcome measures ($30% and $50% pain reduction) were sought from RCTs reporting
interventions with statistically significant efficacies greater than placebo. These data were used to calculate RR and NNT
values.
Results: Of 44 studies identified, 19 were RCTs. Of these, 14 fulfilled the inclusion criteria. Interventions demonstrating
greater efficacy than placebo were smoked cannabis NNT 3.38 95%CI(1.38 to 4.10), topical capsaicin 8%, and recombinant
human nerve growth factor (rhNGF). No superiority over placebo was reported in RCTs that examined amitriptyline (100mg/
day), gabapentin (2.4g/day), pregabalin (1200mg/day), prosaptide (16mg/day), peptide-T (6mg/day), acetyl-L-carnitine (1g/
day), mexilitine (600mg/day), lamotrigine (600mg/day) and topical capsaicin (0.075% q.d.s.).
Conclusions: Evidence of efficacy exists only for capsaicin 8%, smoked cannabis and rhNGF. However,rhNGF is clinically
unavailable and smoked cannabis cannot be recommended as routine therapy. Evaluation of novel management strategies
for painful HIV-SN is urgently needed.
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Introduction
HIV-associated distal sensory neuropathy (HIV-SN) is a
frequently occurring neurological complication of HIV infection.
HIV-SN prevalence has increased despite (or because of) the
introduction of otherwise successful antiretroviral therapy [1].
HIV-SN is one of the most prevalent problems experienced by
people receiving antiretroviral therapy and the associated pain has
a major impact on quality of life in otherwise largely healthy
individuals. HIV-SN is a distal symmetrical axonal, predominantly
sensory polyneuropathy that affects the feet and less frequently the
hands. HIV-SN is comprised of at least two clinically indistin-
guishable, and often coexisting, neuropathies: A distal sensory
polyneuropathy associated with HIV disease itself (HIV-DSP), and
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treatment, Antiretroviral toxic neuropathy (HIV-ATN). HIV-DSP
was recognised early in the HIV pandemic [2] and is associated
with advanced HIV disease [1] [3]. HIV-ATN was initially
observed following the introduction of particular nucleoside
reverse transcriptase inhibitors (NRTI) – stavudine, didanosine
and zalcitabine - the ‘dNRTIs’ [4–5]. The presence of sensory
neuropathic symptoms in an ARV naı ¨ve patient is highly
suggestive of HIV -DSP. Often only a temporal association
between the onset of symptoms and the starting of a particular
ARV agent gives the only hint as to aetiology, as in most other
clinical respects the two are almost identical.
The introduction of combination antiretroviral therapy (cART)
in the mid 1990s dramatically reduced the morbidity and
mortality associated with HIV among patients who have access
to treatment [6]. Life expectancy with HIV in well-resourced
countries is now estimated to be up to two-thirds that of the
general population [7–8]. While the incidence of most neurolog-
ical complications of HIV has fallen with the introduction of
effective therapy, rates of HIV-SN have been rising since the first
effective antiretroviral drugs were developed [9]. Recent estimates
of HIV-SN prevalence among cohorts with access to cART range
from 20% [10] to .50% [11]. Importantly, the available evidence
suggests that HIV-SN prevalence remains high among cART-
treated patients, even in countries where known neurotoxic
antiretroviral drugs such as stavudine are no longer commonly
used. Depending on the population surveyed, HIV-SN, regardless
of previous ARV exposure, has a prevalence of between 13% [12]
and .50% [13–14] of HIV infected individuals, of whom 40%
experience severe pain, $5/10 Numeric Pain Rating Scale
(NPRS), and 90% experiencing some pain, which can be severely
debilitating [1]. In less well-resourced centres, use of stavudine, an
inexpensive and effective antiretroviral, in first-line HIV treatment
remains common despite the high risk of neurotoxicity [15].
Importantly two recent studies have emphasised the continued
and growing global impact of HIV-SN. A large cross-sectional
study of 598 HIV infected individuals in South Africa, reported
that the frequency of symptomatic HIV-SN increases from 23% to
40% following exposure to ART therapy, with 60% being
symptomatic if previously exposed to stavudine [16]. Another
large cross-sectional study from the US studying 1539 HIV
infected individuals has reported that 57%(881) demonstrated
evidence of the presence of HIV-SN, with 38% of these individuals
reporting pain [17].
Current estimates of global HIV prevalence stand at 33 million,
with 2.7 new infections each year and more patients gaining access
to cART [15]. With high rates of HIV-SN now reported globally,
and up to 90% of affected patients experiencing potentially
debilitating neuropathic pain, HIV-SN represents a large and
potentially worsening source of global HIV-related morbidity.
There is an urgent need to understand better the pathogenesis of
HIV-SN, to identify risk factors, and identify and implement
effective preventative and pain management strategies.
Evidence-based guidelines for the pharmacological manage-
ment of neuropathic pain tend to focus on a ‘‘blanket’’ approach of
recommending therapies across the spectrum of neuropathic pain,
irrespective of the underlying condition [18–19]. Recent NICE
guidance for the management of neuropathic pain in ‘‘non-
specialist settings’’ have adopted this approach [20]. This may not
be appropriate for HIV-SN for three main reasons. Firstly,
neuropathic pain is a heterogeneous phenomenon, both within
and across underlying conditions, and evidence obtained from the
study of an analgesic in one condition cannot necessarily be
applied to another [21–22]. Secondly, in high, middle and low
income countries the pain associated with HIV-SN will usually be
managed outside of specialist pain management clinics, so
appropriate, disease specific guidance may be required. Finally,
there are a number of randomised controlled trials (RCTs)
conducted in HIV-SN, which were not identified in the NICE
guidance. Therefore, we have conducted a systematic review and
meta-analysis to elucidate the evidence base for pharmacological
management of neuropathic pain in HIV-SN.
Methods
Eligibility, data sources and search strategy
In accordance with PRISMA [23], we sought to identify RCTs
that included patients with painful HIV-SN and reported at least
one clinically relevant pain outcome measure.
A systematic search, without language restrictions, was
conducted on 20 June 2008, and a follow-up search on 22
February 2010, with the following databases: Medline (from 1966
to date searched), The Cochrane central register of controlled
trials (Cochrane Library 2010, Issue 2), www.clinicaltrials.gov (a
US registry of clinical trials) and www.controlled-trials.com (a
meta-registry of controlled trials). Search terms used were: ‘‘HIV’’
‘‘AIDS’’ ‘‘pain’’ ‘‘painful’’ ‘‘neuropathy’’ ‘‘neuropathic’’, in
combination with ‘‘random’’ ‘‘randomised’’ and ‘‘double-blind-
ed’’. Further trials were identified by hand searching the reference
lists of identified trials and review articles, relevant NICE
guidelines and Health Technology Assessment reports.
Study selection and risk of bias assessment
We excluded animal studies, reviews, letters, abstract-only trials,
open-label trials, and trials that were not randomised. The
identified RCTs then underwent independent quality assessment
by four authors (TJCP, CLC, SC and ASCR) using a 7-point
modified ‘‘Jadad’’ scoring system that assessed the presence and
quality of double-blinding, randomisation, study size and reporting
of withdrawal and drop outs [24–25]. RCTs with a score of less
than five points and studies that enrolled fewer than five HIV-SN
patients were excluded from the systematic review. Scoring
discrepancies between authors were resolved through discussion
and consensus; with final arbitration by ASCR.
Data extraction
Data were extracted from eligible RCTs by one author (TJCP).
Data extracted included: year of publication; study design and
duration; study sample population and characteristics; withdraw-
als; interventions; doses; pain and non-pain related primary and
secondary outcome measures; and adverse events.
Where possible, dichotomous pain improvement outcome data
were extracted from RCTs that reported efficacy superior to
placebo. Intention to treat (ITT) responder rates for 30% and 50%
pain relief were sought for the longest follow-up period reported in
each study. If required, authors were contacted for missing or
unreported data.
RCTs in which the primary pain outcome of a studied
intervention did not show efficacy greater than placebo in the
intention to treat population, were not included in subsequent
analyses.
Statistical analysis
For each intervention the extracted dichotomous outcomes
were used to calculate numbers needed to treat (NNT) by two
authors (TJCP and ASCR), with 95% confidence intervals for
30% and 50% pain improvement responders. We originally
planned to access heterogeneity according to the method of
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studies were used in the meta-analysis, this was felt to be
inappropriate. Similarly, a sensitivity analysis was not performed,
as there were insufficient data. All calculations were undertaken
using Microsoft Excel 2007.
Results
We identified 44 potentially relevant articles (Figure 1). Twenty-
five articles were excluded after screening identified these as being
a review article, letter, open-label study, case report or other non-
Figure 1. PRISMA flow diagram of included randomized controlled trials.
doi:10.1371/journal.pone.0014433.g001
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independently reviewed by four authors (TJCP, CLC, SC and
ASCR). Four articles were excluded at this stage by scoring ,5 out
of 7-points with the modified Jadad score. A further RCT was
excluded as having ,5 HIV-SN patients enrolled. Details of these
excluded RCTs, and therefore of interventions that must be
regarded as not having been adequately tested, are shown in
Table 1.
The remaining 14 RCTs were retained for further analysis
(Table 2). Of the 14 trials retained for further analysis, 13 were of a
parallel group design and one a cross-over design. All were
placebo controlled with one using ‘‘active’’ placebo [28]. Data
extraction was for the longest follow-up period reported by the
article. In most cases this was to the end of the treatment phase,
except for a study of a topical 8% capsaicin [28] that reported data
for 12 weeks after a single treatment application.
In two studies [29] and [30] no reference to ITT analysis was
made. In one of these RCTs studying topical capsaicin 0.075%
efficacy [29] no primary outcome data were published, as it was
reported that no superiority to placebo was seen. In a study of
lamotrigine efficacy [31] only a per protocol (PP) population data
analysis was undertaken. This was reported to show no superiority
over placebo; however no primary outcome data were reported.
Of the four trials that reported superiority of an intervention
over placebo, three reported dichotomous pain outcome measures.
Where possible we used responder rate data for $30% and $50%
improvement in pain as measured using Visual Analogue Scale
(VAS) or Numerical Pain Rating Scale (NPRS). These data were
requested from the authors if they had not been reported.
Acetyl –L-carnitine
Whilst acetyl-L-carnitine has been the subject of six articles [32–
37] in the treatment of painful HIV-SN, only one was an RCT
[36] and eligible for inclusion. This was a parallel group trial of
acetyl-L-carnitine (1000mg/day) and placebo intramuscular
injections. In this RCT acetyl-L-carnitine, in an analysis of the
PP population, showed a modest superiority to placebo. However
an analysis of the ITT population did not show superiority to
placebo: mean change in VAS (0–10cm)(SD) from baseline to the
end of week 2: acetyl-L-carnitine 21.32 (1.84); placebo 20.61
(1.55) p=0.07. Consequently we undertook no further analysis of
this trial.
Amitriptyline and Mexilitine
Two trials [38] and [39] that were included studied the efficacy
of amitriptyline. Both trials compared amitriptyline to placebo and
another intervention. One RCT [38] examined efficacy of
amitriptyline as part of a trial also assessing acupuncture
treatment. However despite being described as a parallel group,
placebo controlled RCT, its design was complex. Consequently
the results of this trial are difficult to evaluate. In particular bias
may have been introduced because of unconventional randomisa-
tion procedures and because true placebo controls were not used.
Specifically, patients were allowed to ‘opt-out’ of being rando-
mised to the amitriptyline arms of the trial based on personal
preference. In addition, many participants included in the analysis
of amitriptyline efficacy, had also received acupuncture or sham
acupuncture, further complicating analysis. Ignoring the method-
ological concerns, amitriptyline demonstrated no superiority to
placebo in the primary outcome measure. The mean change in
Gracely pain scores from baseline to week 14 was 20.26 with
amitriptyline (maximum dose 75mg/day) and 20.30 with placebo.
The difference between amitriptyline and placebo was: 0.00
95%CI(20.18 to 0.19) p=0.99.
The second trial [39] compared amitriptyline, mexilitine and
placebo. This trial was terminated early following an interim
review of results. It was deemed by the trial monitoring board that
further enrolment into the study was unlikely to detect significant
differences in either amitriptyline or mexilitine arms compared to
placebo. No superiority was reported in reducing mean Gracely
pain scores (SD) from baseline to the end of treatment week 8 for:
amitriptyline (maximum dose 100mg/day) 20.31 (0.31); mexili-
tine 20.23 (0.41); compared to placebo 20.20 (0.30).
Smoked Cannabis
The original literature search found four articles related to
cannabinoid use and painful HIV-SN. Only two were RCTs [40–
41]. The excluded articles included one clinical survey [42] and
one review article [43].
One of these included articles [41] was a cross-over study that
compared the efficacy of smoked cannabis (maximum tolerated
dose 1 to 8% D-9-tetrahydrocannabinol q.d.s.) to placebo
cigarettes in reducing subjects pain measured using the Descriptor
Differential Scale (DDS). The DDS is a ratio scale (0 to 20)
containing 24 words describing pain intensity and unpleasantness.
Table 1. Studies excluded from the analysis.
Reference Treatment Primary Reason for Exclusion
[37] Acetyl-L-carnitine Review
[61] Acetyl-L-carnitine Review
[43] Cannabinoids Review
[62] Lamotrigine Review
[63] Antidepressants Review
[64] Herbal medicine Review
[44] 8% capsaicin patch Open-label
[45] 8% capsaicin patch Abstract
[33] Acetyl-L-carnitine Open-label
[34] Acetyl-L-carnitine Open-label
[65] Recombinant human NGF Open-label
[66] Flecainide Open-label
[67] 5% lidocaine patch Open-label
[68] Acupuncture Letter
[69] Acupuncture Letter
[70] Acupuncture Letter
[46] Gabapentin Letter
[47] Gabapentin Letter
[49] Gabapentin Case report
[71] Prednisolone Case report
[48] Gabapentin Abstract
[42] Smoked cannabis Other non-RCT
[35] Acetyl-L-carnitine Other non-RCT
[72] Acupuncture Other non-RCT
[32] Acetyl-L-carnitine Other non-RCT
[73] 5% lidocaine patch Modified Jadad score ,5
[74] Mexiletine Modified Jadad score ,5
[75] Memantine Modified Jadad score ,5
[76] Nimodipine Modified Jadad score ,5
[52] Lamotrigine ,5 patients enrolled
doi:10.1371/journal.pone.0014433.t001
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PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e14433Smoked cannabis was reported to be superior to placebo in
reducing DDS from baseline to end of treatment day five in the PP
population. The median difference between cannabis and placebo
was 23.3 out of 20; p=0.016. No data were reported for the ITT
analysis, however the authors stated that the PP analysis was
similar to the ITT analysis with p=0.02. VAS data not reported
by the authors, but was supplied on request, relating to cannabis
and placebo subjects who reported a $30% (18/34 and 7/34
respectively) and $50% (13/34 and 4/34 respectively) improve-
ment in pain intensity.
This trial reported a high proportion of inadvertent unblinding
amongst subjects following dose titration with smoked cannabis
cigarettes in the treatment arms, but not with placebo cigarettes.
A second study [40] compared smoked cannabis (3.56% D-9-
tetrahydrocannabinol t.d.s.) to placebo cigarettes in a parallel
group RCT. Smoked cannabis was shown to be superior to
placebo in reducing pain from baseline to end of treatment day 5
in the ITT analysis: cannabis 234% (IQR 271 to 216), placebo
217% (IQR 229 to 8) p=0.03. More subjects reported $30%
VAS improvement with smoked cannabis compared to the
placebo: 13/27 and 6/27 respectively.
Inclusion into the study required subjects to have had previous
exposure to cannabis, with current users asked to discontinue prior
to the study. Of note no attempt was made to assess unintentional
unblinding during the course of the study, which may have been
high due to subjects’ previous experience with smoked cannabis.
Using the ITT analysis dichotomous VAS data from both trials,
an NNT for smoked cannabis was calculated as 3.38 95%CI (2.19
to 7.50) (Table 3)
Topical Capsaicin
Four trials [44] [29] [28] and [45] were found that assessed
topical capsaicin efficacy in painful HIV-SN. Two reports were
excluded from further analysis; one was an open-label study [28]
and the other has been reported in abstract form only [45]. Of the
included trials, one [29] examined the efficacy of topical capsaicin
0.075% cream in a parallel group RCT. The authors stated that
no superiority of capsaicin 0.075% over placebo in mean
improvement in a numeric rating score (NRS) (0–10) was seen,
however only graphical data were presented.
A second study [28] examined topical capsaicin 8%. Patients
received either the 8% patch or an active placebo (capsaicin
0.04%) in a single application lasting either 30, 60 or 90 minutes.
Following this single application patients were followed-up for 12
weeks. Capsaicin 8% was found to be superior to placebo in the
percentage reduction of the NPRS (SD) from baseline to week 2
to 12: 8% capsaicin: 222.8 (30.6); compared to placebo: 210.7
(30.8), (p=0.0026). The study also reported responder rates as
percentage of patients measured on the NPRS who experienced
$30% mean reduction in pain: capsaicin 8%: 76/225; placebo
(capsaicin 0.04%): 15/82; p=0.0092. It is not possible to
calculate an NNT that is strictly comparable to those calculated
for other studies included in this review since the placebo control
used here was not pharmacologically inactive. However, as an
informative exercise using these data, and presuming that the
control capsaicin 0.04% is a true placebo, an NNT of 6.46
95%CI(3.86–19.69) was calculated for treatment with capsaicin
8% patch.
Gabapentin
Only one retrieved report related to treatment of painful HIV-
SN with gabapentin was an RCT. Four additional articles were
excluded. Two were letters [46–47] one an abstract [48], and one
a case series [49]. The included study [30] compared gabapentin
(titrated to a maximum of 2400mg/day) to placebo in a parallel
group RCT. At the longest treatment period assessed, no
difference in efficacy was reported between gabapentin and
placebo groups for the primary outcome measure, median change
in VAS (0–100mm) baseline to end of week 4: gabapentin: 244.1,
placebo: 229.8. No indication of variance or p value was
documented.
It is noteworthy that this trial demonstrated an unusual placebo
response. The placebo subjects’ pain VAS baseline remained
unchanged for the first two weeks, after which a stronger placebo
response followed to week 4. This unusual placebo response may
have contributed to the apparent superiority of gabapentin over
placebo at week 2, which was not evident at week 4.
Pregabalin
One large multi-centre RCT [50] examined the efficacy of
pregabalin, titrated over 2 weeks to a maximum tolerated dose up
to 1200mg/day, in a multicentre, 14 week parallel group, placebo
controlled RCT. No superiority of pregabalin over placebo in the
primary pain outcome measure was reported: mean change in
NPRS baseline to end of week 14: pregabalin 22.88; placebo
22.63, p=0.39.
Table 3. Summary of RCTs which demonstrated treatment superior to placebo, for which Relative Risk and Number Needed to
Treat values could be calculated.
Active Treatment
(maximum tested
dose)
Number of patient
Episodes
Benefit Efficacy on
Treatment ($30%
improvement VAS
Efficacy on Placebo
($30% improvement
VAS) RR (95% CI) NNT (95% CI)
Smoked
cannabis
Abrams et al
2007 [40]
Smoked cannabis:
3.56% D-9-
tetrahydrocannabinol
55 (50) 13/27 6/28 2.17 (0.97 to 4.86) 3.86 (1.98 to 71.11)
Ellis et al
2009 [41]
Smoked cannabis:
8% D-9-tetrahydro-
cannabinol
68 (56) 18/34 7/34 2.57 (1.24 to 5.35) 3.09 (1.98 to 9.30)
Abrams et al
[40]+Ellis et al
[41]
Combined smoked
cannabis studies
122 (106) 31/61 15/61 2.38 (1.38 to 4.10) 3.38 (2.19 to 7.50)
doi:10.1371/journal.pone.0014433.t003
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Three trials assessing the efficacy of lamotrigine in painful HIV-
SN were identified [51,52] and [29,31]). One trial [52], enrolled
only one painful HIV-SN patient (to the placebo control group)
and was therefore excluded from further analysis. The included
lamotrigine trials [51] and [31] were both conducted by the same
group; with [51] being smaller and preceding [31]. The smaller
study [51] did demonstrate some efficacy superior to placebo when
the primary outcome for the PP population was analysed.
However in the ITT analysis with ‘last value carried forward’
(LVCF), lamotrigine was not superior to placebo: improvement in
mean Gracely pain score (SE): lamotrigine: 20.242 (0.009);
placebo: 20.183 (0.087); (p=0.65). The large number of drop-
outs in the lamotrigine group (n=11 of 20) compared to placebo
(n=3 of 22) suggest a narrow therapeutic index and make
interpretation of the trial results difficult.
Similarly the larger trial [31], where participants were stratified
according to previous exposure to neurotoxic ARVs, did not
demonstrate a superiority of lamotrigine over placebo for the
primary outcome measure (mean improvement in Gracely pain
score) in the total cohort or in either stratum. However lamotrigine
did show superiority to placebo in the neurotoxic ARV-exposed
stratum in a secondary outcome measure, mean improvement in
VAS (0–100mm) baseline to end of treatment: lamotrigine: 227.1;
compared to placebo: 29.0; p=0.003.
For each stratum the number of responders ($30% improve-
ment in VAS) were calculated from the published data. For the
neurotoxic ARV stratum: lamotrigine 36/62, placebo 7/30
(p=0.02) and for no exposure to neurotoxic ART: lamotrigine
46/88, placebo 21/47. As an informative exercise using these data
the NNT for lamotrigine was calculated for each stratum, and for
the overall trial. Subjects with exposure to neurotoxic ARVs: 2.88
95%CI(1.84 to 6.57); no exposure to neurotoxic ARVs: 13.17
95%CI(3.96 to 29.95) and for the unstratified population: 6.09
95%CI(3.51 to 23.08)(Not included in Table 3 as no superiority of
lamotrigine over placebo was demonstrated for any primary
endpoint).
NGF
One RCT [53] examined the efficacy of subcutaneous
recombinant human Nerve Growth Factor (rhNGF) in the
treatment of painful HIV-SN. This study assessed two doses (0.1
and 0.3mg/kg) given twice weekly compared with placebo for 18
weeks. rhNGF was superior to placebo for the primary outcome
measure in the ITT analysis; median change of the Gracely pain
score from baseline to end of week 18: rhNGF 0.1mg/kg: 20.18
(20.10 to 20.25) p=0.05, 0.3mg/kg: 20.21 (20.14 to 20.29)
p=0.04, and placebo: 0.06 (+0.01 to 20.14).
No significant dose effect was reported and no differential effect
was seen based on baseline stratification of subjects according to
neurotoxic ARV drug exposure. As rhNGF was reported to be
associated with myalgia, there may have been inadvertent
breaking of the blinding.
Dichotomous data were requested from the authors however we
were unable to calculate RR and NNT values for rhNGF from the
data provided.
Prosaptide and Peptide –T
Two trials [54,55] examined the efficacy of the novel agents in
placebo controlled parallel group RCTs. One [55] reported the
use of subcutaneous prosaptide (maximum dose of 16mg/day)
over 6 treatment weeks and did not report efficacy superior to
placebo in the primary outcome measure; mean change in Gracely
pain score baseline to week 6. The study was terminated after a
planned interim futility analysis. Another trial [54] studied efficacy
of intranasal peptide T (maximum dose 6mg/day), over 12
treatment weeks, but reported no superiority over placebo in the
primary outcome measure; mean change in a modified Gracely
pain score baseline to end of week 12.
Discussion
This systematic review found that RCT evidence of analgesic
efficacy superior to placebo in the context of HIV-SN pain exists
only for smoked cannabis, rhNGF and high dose (8%) topical
capsaicin. Several other agents have been examined in high
quality RCTs and found to be no more effective than placebo for
managing HIV-SN pain in the doses examined, specifically acetyl-
L carnitine (1g/day), amitriptyline (100mg/day), topical capsaicin
0.075%, gabapentin (2.4g/day), mexilitine (600mg/day), peptide –
T (6mg/day), pregabalin(1200mg/day), lamotrigine (600mg/day)
and prosaptide (16mg/day). Therefore, there is evidence that both
of the first line therapies (pregabalin and amitriptyline) recom-
mended in the NICE guidance for non-specialist management of
neuropathic pain show no superiority to placebo in the
management of pain in HIV-SN [20].
Of the pharmacological interventions shown to be effective for
HIV-SN in RCTs, only topical capsaicin 8% is currently approved
for marketing for neuropathic pain indications. In Europe 8%
capsaicin has been approved for the treatment of peripheral
neuropathic pain in non-diabetic adults, whilst the U.S. Food and
Drug Administration (FDA) has approved its use only for the
indication of post herpetic neuralgia. However, it should also be
borne in mind that we located a preliminary report (conference
abstract only and therefore excluded from the systematic review) of
another parallel group RCT which included 494 patients with
HIV-SN in which topical 8% capsaicin was compared to 0.04%
topical capsaicin [45]. No analgesic superiority of 8% capsaicin
over 0.04% was demonstrated. rhNGF therapy is not currently
clinically available and both legal and mental health issues
preclude routine recommendation of long term smoked cannabis
for pain management [56].
This systematic review represents a comprehensive review of the
literature relating to the pharmacological management of painful
HIV-SN. It used a predefined protocol for the initial literature
search, data extractionand analysis. There wasalsostrict adherence
to inclusion quality criteria as assessed by four independent authors
using the modified Jadad score, a tool that assesses each study for
potential bias as well as evaluating study power.
This systematic review was limited by the paucity of high quality
RCTs examining pharmacological treatment of painful HIV-SN.
Additionally the heterogeneity of the included studies design and
size made evaluation and comparison of trials difficult. In
particular, use of the Gracely pain scale (GPS) in five of the 15
included RCTs made evaluation and inter-study comparison
complicated. The GPS is a log unit pain outcome measure that is
not a frequently used measure outside trials of HIV-SN. In a
recent consensus statement regarding core chronic pain outcome
measures [57] it was not one of the recommended pain scales.
Several of the studies utilising the Gracely pain score also included
more validated secondary pain outcome measures such as either a
VAS score or a NPRS. These were used here in preference to the
Gracely pain score in the calculation of NNT and RR.
The Jadad tool has been validated and used widely to identify
common and major sources of experimental bias in RCTs
identified in systematic reviews. Nevertheless, whilst the use of
the modified Jadad score improves the probability that only high
quality RCTs were included in the systematic review, its use may
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PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e14433conceivably have biased our systematic review in favour of more
recently tested agents. The RCTs associated with these agents now
routinely report the information required by the modified Jadad
tool, because of the nature of the evolution of RCT methodology
over the past few years.
Both of the RCTs that examined the efficacy of smoked
cannabis, were of high quality, however the apparent marked
superiority of smoked cannabis to placebo cigarettes should be
tempered by the high proportion of potential unblinding measured
in [41] (92% correctly guessing treatment allocation after
treatment crossover), and its lack of measurement in [40] despite
participants having all had previous experience of smoked
cannabis. In a similar manner, the RCT investigating recombinant
human NGF demonstrated a high degree of unblinding related to
injection site myalgia, which when accounted for in a separate
analysis reported a more attenuated treatment-related difference
which consequently lost statistical significance.
Lamotrigine was the subject of two high quality RCTs. Both
failed to show superiority over placebo in the primary pain
outcome measure, improvement in the GPS in the ITT
population. However, in the larger of the two RCTs, analysis of
a secondary pain outcome measure, mean improvement in VAS,
did demonstrate efficacy superior to placebo in the subpopulation
of subjects who had been previously exposed to neurotoxic ARTs.
If this stratum alone is examined an NNT of 2.88 is calculated.
Most of the included RCTs did not stratify subjects with painful
HIV-SN according to their exposure to neurotoxic ARTs. This
stratification was instrumental in demonstrating an efficacy of
lamotrigine in neurotoxic ART exposed painful HIV-SN subjects.
It is possible to speculate that a similar strategy of stratifying other
RCTs might have elucidated other agents with sub-group efficacy,
despite lack of observed analgesic efficacy in an unstratified painful
HIV-SN subject population. Additionally, the included RCTs
were not uniform in their approach to the use of concomitant
analgesics; whilst most allowed continued use of drugs at stable
doses, two elected to stop them [30] [58]. The use of such
concomitant analgesics, and also the inclusion of participants with
previously failed therapies, may conceivably have influenced the
outcomes of these RCTs.
Gabapentin and pregabalin were the subject of two high quality
RCTs in which neither agent was shown to be superior to placebo.
This contrasts with the efficacy of these agents demonstrated in
other peripheral neuropathic pain conditions [20] [59] [18,19].
However the gabapentin study was small, with only 30 patients
randomised [30]. This finding may therefore represent a ‘failed
trial’ rather than a true lack of efficacy.
Amitriptyline efficacy was examined in two large RCTs. The
evaluation of one study [38] was made difficult by a complicated
study design that may have not been truly randomised or placebo
controlled. However the finding that amitriptyline did not display
superior analgesic efficacy than placebo in the context of HIV-SN
is supported by a similar finding a second, higher quality RCT
[39]. Again, this finding directly contrasts with evidence of efficacy
for tricyclic antidepressants in a range of other peripheral
neuropathic pain conditions [20] [59] [19] [18].
Capsaicin 0.075% cream was the subject of a small RCT
enrolling only 26 subjects. The authors stated that capsaicin
0.075% did not demonstrate statistically significant superiority to
placebo in the primary pain outcome measure. However, outcome
data were published only in a graphical representation of mean
current pain scores from baseline to the end of treatment. From
this graph there does appear to be a trend for capsaicin to be
superior to placebo at this final time point measured at week 4.
However a high drop-out rate in both arms resulted in only 6/11
patients remaining in the capsaicin group, and only 8/15 in the
placebo group. It is therefore difficult to determine from this study
if capsaicin 0.075% was indeed without efficacy. This has two
implications: the first being that capsaicin 0.075% might have
some degree of clinically relevant efficacy in painful HIV-SN; and
secondly, if capsaicin 0.075% is indeed efficacious, then the use of
a similar concentration (capsaicin 0.04%) as an active placebo in
the large capsaicin 8% patch RCT would change the design of this
study from a placebo controlled to a superiority approach.
In the treatment of painful HIV-SN, the lack of efficacy
compared with placebo of many agents with proven efficacy in
other forms of neuropathic pain has implications in the
understanding of neuropathic pain in general. These findings
further support the hypothesis that neuropathic pain cannot be
considered as a single symptom with a single pathogenesis [21,22].
A more mechanistic approach to the treatment of specific types of
neuropathic pain is therefore warranted as has been established in
trigeminal neuralgia and post herpetic neuralgia. Equally, caution
should be exercised in the use of neuropathic pain treatment
algorithms that do not consider these potential mechanistic
differences, as their rationale may be fundamentally flawed.
The absence of studies examining the efficacy of opioid use in
painful HIV-SN is notable and mandates additional research.
Opioids have shown efficacy in other neuropathic pain conditions
[18] [59] [19]. Furthermore, the efficacy of duloxetine in diabetic
neuropathy, a condition that has similarities to HIV-SN, may
suggest that it is worth investigating [20]. In addition, the efficacy
of cannabis in HIV-SN would suggest that cannabinoids with an
appropriate therapeutic index when delivered by a mechanism
other than smoking might be worthy of investigation [56].
Conclusions
On the basis of current published evidence, topical capsaicin
8%, smoked cannabis and Nerve Growth Factor have evidence of
efficacy in pain associated with HIV-SN. However this is
potentially contentious, as a recent larger RCT, currently reported
in abstract form only, has suggested this treatment is not superior
to placebo [45]. Some commonly recommended analgesics,
including opioids, have not been formally studied for the
management of painful HIV-SN.
The current evidence base available for the treatment of painful
HIV-SN is at odds with the recommendations made by NICE for
neuropathic pain management in the non-specialist situation. This
indicates the potential dangers of extrapolating efficacy from one
neuropathic pain condition to another where efficacy has not been
directly assessed. In particular amitriptyline, pregabalin, and
gabapentin have been demonstrated to have no superiority to
placebo in the treatment of painful HIV-SN.
With an estimated 33 million people living with HIV and more
gaining access to ARV every day, the management of HIV-SN
associated neuropathic pain is a problem of major global
significance. There is an urgent need for the development of
effective, evidence based analgesic strategies for this common
condition. Gene microarrays have been used to identify novel drug
targets [60]. Ongoing evaluation of both novel analgesics and
existing untested strategies for HIV-SN is a clear research priority.
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